Neuroimaging Studies

该中心的主要目的是开发和评估戒烟前适应治疗香烟成瘾。该项目的首要目标是评估戒烟前药物作用的神经机制。在设计并行项目1。临床试验（PD: Rose）， 100名吸烟者将被分配到四个治疗组中的一个。在所有四组中，参与者将在戒烟前的两周内继续吸他们常用品牌的香烟。对照组（CNTRL）将在戒烟前两周佩戴安慰剂贴片。第二组在戒烟前两周佩戴21mg /d的贴片（仅限nrt）。第三组将在第二周从佩戴尼古丁贴片改为服用伐尼克兰（NRT¿¿VAR）。第四组在第二周服用安非他酮SR和NRT （NRT+BUP）。参与者将在戒烟后12小时进行在线扫描。

The primary aim of the proposed center is to develop and evaluate pre-cessafion adapfive treatments for cigarette addiction. The overarching goal of this project is to evaluate the neural mechanisms that underiie pre-cessation medication effects. In a design paralleling Project 1. Clinical Trials (PD: Rose), 100 smokers will be assigned to one of four treatment arms. In all four arms, participants will confinue to smoke their usual brand of cigarettes in the two weeks prior to quitting smoking. The control (CNTRL) group will wear a placebo patch in the two weeks prior to their quit date. A second group will wear a 21 mg/d patch for the two weeks prior to the quit date (NRT-Only). A third group will switch from wearing a nicotine patch to taking varenicline in the second week (NRT¿¿VAR). A fourth group will take bupropion SR in addition to NRT in the second week (NRT+BUP). Participants will be scanned at tiaseline and again 12 hrs after quitting smoking. During scanning, we will measure brain reactivity to smoking cues and cerebral blood fiow. Common and unique effects of pre-cessation pharmacotherapies will be identified. Based on preliminary data, we hypothesize that pre-cessation treatment will result in lower brain reactivity to smoking cues and cerebral blood flow following quitfing smoking. We also hypothesize that baseline brain funcfion will be predictive of pre- and post-quit treatment response. The proposed project builds upon the investigative team's experience and is highly integrated with the center's other projects and cores.